

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

## Public Health

journal homepage: [www.elsevier.com/puhe](http://www.elsevier.com/puhe)

## Short Communication

# Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK



L. Varghese<sup>a,\*</sup>, D. Curran<sup>b</sup>, E. Bunge<sup>c</sup>, H. Vroiling<sup>c</sup>, F. van Kessel<sup>c</sup>,  
A. Guignard<sup>b</sup>, G. Casabona<sup>b</sup>, A. Olivieri<sup>b,1</sup>

<sup>a</sup> GSK Vaccines, Singapore<sup>b</sup> GSK Vaccines, Wavre, Belgium<sup>c</sup> Pallas Health Research and Consultancy, Rotterdam, Netherlands

## ARTICLE INFO

## Article history:

Received 7 January 2016

Received in revised form

18 July 2016

Accepted 13 October 2016

Available online 18 November 2016

Live attenuated vaccines (LAVs) offer strong cellular and antibody responses for protecting at-risk populations from severe infectious diseases.<sup>1</sup> Examples include the measles, mumps, herpes zoster, varicella, and yellow fever vaccines. LAVs, however, are usually contraindicated for individuals with immunocompromising (IC) conditions because of a low risk, based on clinical evidence or theoretical considerations, that the partially attenuated vaccine strain could revert to the wild-type form and cause disease.<sup>2–4</sup> At the same time, individuals with IC conditions need vaccines because they are at an increased risk of severe infections.<sup>5–7</sup> In cases where alternatives to live vaccines are not available for individuals with IC conditions, the risk of potential adverse events from the vaccine must be weighed against the risk of disease from the wild-type pathogen.

To make informed decisions about developing or offering alternative vaccines to people with IC conditions, an estimate of

the size of the IC population is needed. The only estimate to date, published in 2001, suggested that close to 10 million individuals in the USA or 3.6% of the population had IC conditions, although the authors explained that this was a ‘back of the envelope’ calculation based solely on the sum of the numbers of organ transplants, individuals with diagnosed and undiagnosed human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and patients with cancer.<sup>8</sup>

To better understand the unmet need for alternative vaccines in the adult IC population, we estimated the total burden of 11 main IC conditions listed as contraindicated conditions in international vaccination guidelines and recommendations.<sup>9–12</sup> The GLOBOCAN database<sup>13</sup> was used for cancer incidence and prevalence rates. For all other IC conditions, incidence and prevalence rates were obtained by a search of PubMed and, where data were unavailable, by a search for surveillance data available online (Table 1). When more than one source of data with the necessary age stratification (18+ years) was available, we selected the one with the highest quality, most representative data using a tool adapted from the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies.<sup>14</sup>

Although our initial goal was to make estimates for 10 countries, our search of peer-reviewed articles and surveillance databases yielded sufficient data only for the USA and UK. Based on the data we collected, we estimated that in 2012, 7.6 million adults (≥18 years old) in the USA and 1.7 million adults in the UK had one of the IC conditions listed in Table 1.

\* Corresponding author. GSK Vaccines R&D – Asia-Pacific & North Asia, 150 Beach Road, #22-00 Gateway West, 189720, Singapore.

E-mail address: [lijoy.x.varghese@gsk.com](mailto:lijoy.x.varghese@gsk.com) (L. Varghese).

<sup>1</sup> Current affiliation: Alexion Pharmaceuticals, Lausanne, Switzerland.

<http://dx.doi.org/10.1016/j.puhe.2016.10.013>

0033-3506/© 2016 GlaxoSmithKline SA. Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1 – Incidence and prevalence of IC conditions in adults in the USA and UK.**

IC condition <sup>a</sup>	Measure	USA			UK		
		No. per 100,000 persons or person-years	Year	Estimated no. of cases <sup>b</sup>	No. per 100,000 persons or person-years	Year	Estimated no. of cases <sup>c</sup>
Solid organ malignancies	Prevalence	362.05 <sup>d</sup>	2012	869,593	320.79 <sup>d</sup>	2012	160,977 <sup>e</sup>
	Incidence	460.57 <sup>d</sup>	2012	1,106,224	443.29 <sup>d</sup>	2012	222,448
Haematological malignancies	Prevalence	35.14 <sup>d</sup>	2012	84,401	33.31 <sup>d</sup>	2012	16,715
	Incidence	50.41 <sup>d</sup>	2012	121,078	48.91 <sup>d</sup>	2012	24,543
Psoriasis	Prevalence	883 <sup>f</sup>	1996–2009	2,120,842	1520.2 <sup>g</sup>	1987–2002	919,502 <sup>e</sup>
	Incidence	78.9 <sup>h</sup>	1970–1999	191,065 <sup>e</sup>	140 <sup>i</sup>	1996–1997	72,029 <sup>e</sup>
Systemic lupus erythematosus	Prevalence	143.75 <sup>j</sup>	2000–2004	512,016 <sup>e</sup>	49.31 <sup>k</sup>	1998	24,746 <sup>e</sup>
	Incidence	7.22 <sup>l</sup>	2003–2008	18,127 <sup>e</sup>	3.02 <sup>k</sup>	1992–1998	1,789 <sup>e</sup>
Rheumatoid arthritis	Prevalence	720 <sup>m</sup>	1995–2007	1,729,339	570 <sup>n</sup>	2010	286,029
	Incidence	40.9 <sup>m</sup>	1995–2007	99,195 <sup>e</sup>	48 <sup>o</sup>	1990–1995	20,881 <sup>e</sup>
Crohn's disease	Prevalence	96.3 <sup>p</sup>	2002	308,683 <sup>e</sup>	157 <sup>q</sup>	2007	78,784
	Incidence	6.3 <sup>p</sup>	1996–2002	18,067 <sup>e</sup>	9.56 <sup>q</sup>	2003–2007	4,725 <sup>e</sup>
Ulcerative colitis	Prevalence	155.8 <sup>p</sup>	2002	514,792 <sup>e</sup>	243 <sup>r</sup>	2002	121,939
	Incidence	12.0 <sup>p</sup>	1996–2002	36,496 <sup>e</sup>	ND	ND	ND
HIV/AIDS	Prevalence	324.6 <sup>s</sup>	2009	830,101 <sup>e</sup>	150 <sup>t</sup>	2012	75,271
	Incidence	19.5 <sup>s</sup>	2010	48,248 <sup>e</sup>	10 <sup>t</sup>	2012	5018
HSCT	Prevalence	ND	ND	ND	ND	ND	ND
	Incidence	4.0 <sup>u</sup>	2006	9,607 <sup>e</sup>	ND	ND	ND
Solid organ transplant	Prevalence	ND	ND	ND	ND	ND	ND
	Incidence	10.9	2012	26,281 <sup>v</sup>	9.27	2013–2014	4,655 <sup>e,w</sup>
End-stage renal disease	Prevalence	190.09 <sup>x</sup>	2011	650,483 <sup>e</sup>	86.32 <sup>y</sup>	2011	55,624 <sup>e</sup>
	Incidence	35.71 <sup>x</sup>	2011	123,125 <sup>e</sup>	10.70 <sup>z</sup>	2011	6,944 <sup>e</sup>
Total	Prevalence	–	–	7,620,252	–	–	1,739,587
	Incidence	–	–	1,797,512	–	–	363,031

The GLOBOCAN database was used for cancer incidence and prevalence rates. For all other IC conditions, peer-reviewed articles in English published in the last 5 years were identified by a search of PubMed on October, 2013 using the following search string: [IC condition] AND (incidence OR prevalence) AND [country]. When more than one publication was found with the necessary age stratification (18+ years), data from the highest quality study were selected using a tool adapted from the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies (<http://www.ehphp.ca/tools.html>). When data were not found in the initial search, the search was extended to the last 10 years. If data were still not found, they were obtained from online global surveillance databases when available, or if not, from country-specific surveillance databases identified using the Google search engine. Abbreviations: HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HSCT, haematopoietic stem cell transplant; ND, no data; Ref, reference; No, number; IC, immunocompromising.

<sup>a</sup> Included conditions were based on: Habel et al. *Cancer Epidemiol Biomarkers Prev.* 2013;22:82–90; US Centers for Disease Control and Prevention. CDC Health Information for International Travel 2014. New York: Oxford University Press; 2014; Lupus Canada. Immunosuppressive drugs used in treating lupus. 2007. Available from <http://www.lupuscanada.org/pdfs/factsheets/Immuno-Online.pdf>; Trevillian P. *Australian Prescriber.* 2006;29:102–8; Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 1993;42:1–18; Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 2011;60:1–64; Fiore et al. *MMWR Recomm Rep.* 2010; 59:1–62; and Harpaz et al. *MMWR Recomm Rep.* 2008;57:1–30.

<sup>b</sup> Based on the 2012 adult population in the USA (240,185,952). Source: <http://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk>.

<sup>c</sup> Based on the 2012 adult population in the UK (50,180,600). Source: <http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk-england-and-wales-scotland-and-northern-ireland/mid-2011-and-mid-2012/rft-mid-2012-uk-population-estimates.zip>.

<sup>d</sup> International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx).

<sup>e</sup> Cases presented are based on age-standardized rates, which were calculated based on 2012 population data using age-specific rates reported (where available) and the 2012 census data to estimate the cases for the ≥18 years old population.

<sup>f</sup> Asgari et al. *Pharmacoepidemiol Drug Saf.* 2013;22:842–9.

<sup>g</sup> Gelfand et al. *Arch Dermatol.* 2005;141:1537–41.

<sup>h</sup> Icen et al. *J Am Acad Dermatol.* 2009;60:394–401.

<sup>i</sup> Huerta et al. *Arch Dermatol.* 2007;143:1559–65.

<sup>j</sup> Feldman et al. *Arthritis Rheum.* 2013;65:753–63.

<sup>k</sup> Nightingale et al. *Pharmacoepidemiol Drug Saf.* 2006;15:656–61.

<sup>l</sup> Furst et al. *Lupus.* 2013;22:99–105.

<sup>m</sup> Myasoedova et al. *Arthritis Rheum.* 2010;62:1576–82.

<sup>n</sup> Jordan et al. *Ann Rheum Dis.* 2014;73:212–8.

<sup>o</sup> Humphreys et al. *Ann Rheum Dis.* 2013;72:1315–20.

<sup>p</sup> Herrinton et al. *Am J Gastroenterol.* 2008;103:1998–2006.

<sup>q</sup> Steed et al. *Scott Med J.* 2010;55:22–5.

<sup>r</sup> Stone et al. *Eur J Gastroenterol Hepatol.* 2003;15:1275–80.

<sup>s</sup> Prejean et al. *J Community Health.* 2013;38:414–26.

<sup>t</sup> Aghaizu et al. HIV in the United Kingdom: 2012 Report. London: Public Health England; 2012. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/326601/HIV\\_annual\\_report\\_2013.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/326601/HIV_annual_report_2013.pdf).

Download English Version:

<https://daneshyari.com/en/article/5122776>

Download Persian Version:

<https://daneshyari.com/article/5122776>

[Daneshyari.com](https://daneshyari.com)